Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
(    O
R)-pantothenate    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
(R)-pantoate    B-HydroxyAcid114613922
and    O
beta    O
-    O
alanine    O
.    O

Ingredients    O
used    O
as    O
enhancements    O
in    O
the    O
water    O
include    O
hydroxycitric    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
chromium    O
,    O
epigallocatechin    O
gallate    O
,    O
potassium    O
,    O
vitamin    O
C    O
,    O
vitamin    O
B6    O
and    O
vitamin    O
B12    O
.    O

Fusidic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
is    O
a    O
steroid    O
antibiotic    O
that    O
is    O
often    O
used    O
topically    O
in    O
creams    O
and    O
eyedrops    O
but    O
may    O
also    O
be    O
given    O
systemically    O
as    O
tablets    O
or    O
injections    O
.    O

The    O
company    O
launched    O
Fucidin    B-HydroxyAcid114613922
to    O
be    O
used    O
to    O
treat    O
staphylococcus    O
infections    O

After    O
her    O
successful    O
publications    O
,    O
Barber    O
was    O
hired    O
by    O
the    O
Medical    O
Research    O
Council    O
to    O
study    O
semisynthetic    O
penicillin    O
,    O
cephalosporin    O
,    O
fucidin    B-HydroxyAcid114613922
,    O
lincomycin    O
,    O
and    O
pristinamycin    O
.    O

Methicillin    O
-    O
resistant    O
Staphylococcus    O
aureus    O
infections    O
may    O
be    O
treated    O
with    O
a    O
combination    O
therapy    O
of    O
fusidic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
and    O
rifampicin    O
.    O

Boswellic    B-HydroxyAcid114613922
acids    I-HydroxyAcid114613922
are    O
a    O
series    O
of    O
pentacyclic    O
triterpene    O
molecules    O
that    O
are    O
produced    O
by    O
plants    O
in    O
the    O
genus    O
"    O
Boswellia    O
"    O
.    O

It    O
is    O
the    O
most    O
common    O
ingredient    O
of    O
traditional    O
herbal    O
drinks    O
in    O
Taiwan    O
containing    O
different    O
phenolic    O
compounds    O
:    O
kaempferol    O
3-O-α-l    O
-    O
rhamnopyranoside-7-O-[α-d    O
-    O
apiofuranosyl-(1    O
-    O
2)-β-d    O
-    O
glucopyranoside    O
]    O
,    O
7-O    O
-    O
caffeoyl    B-HydroxyAcid114613922
3-O-β-d    O
-    O
glucopyranoside    O
,    O
hispidin    O
4-O-β-d    O
-    O
glucopyranoside    O
,    O
kaempferol    O
3-O-α-l    O
-    O
rhamnopyranoside-7-O-β-d    O
-    O
glucopyranoside    O
,    O
caffeic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
5-O    O
-    O
caffeoylquinic    O
acid    O
,    O
3,5-di    O
-    O
O    O
-    O
caffeoylquinic    O
acid    O
and    O
4,5-di    O
-    O
O    O
-    O
caffeoylquinic    O
acid    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
3,4-dihydroxy    O
-    O
L    O
-    O
phenylalanine    O
(    O
L    O
-    O
DOPA    O
)    O
,    O
and    O
two    O
products    O
,    O
trans-caffeate    B-HydroxyAcid114613922
and    O
NH3    O
.    O

Caffeic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
–    O
burdock    O
,    O
hawthorn    O
,    O
artichoke    O
,    O
pear    O
,    O
basil    O
,    O
thyme    O
,    O
oregano    O
,    O
apple    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
3,4-dihydroxy-trans-cinnamate    B-HydroxyAcid114613922
(    O
caffeic    O
acid    O
)    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
3-methoxy-4-hydroxy-trans-cinnamate    B-HydroxyAcid114613922
(    O
ferulic    O
acid    O
)    O
.    O

As    O
an    O
unpigmented    O
fruit    O
flesh    O
,    O
rambutan    O
does    O
not    O
contain    O
significant    O
polyphenol    O
content    O
,    O
but    O
its    O
colorful    O
rind    O
displays    O
diverse    O
phenolic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
such    O
as    O
syringic    O
,    O
coumaric    O
,    O
gallic    O
,    O
caffeic    B-HydroxyAcid114613922
,    O
and    O
ellagic    O
acids    O
having    O
antioxidant    O
activity    O
in    O
vitro    O
.    O

Some    O
chemicals    O
found    O
in    O
trace    O
amounts    O
in    O
food    O
,    O
and    O
some    O
dietary    O
supplements    O
,    O
also    O
have    O
been    O
shown    O
in    O
inhibit    O
5-LOX    O
,    O
such    O
as    O
baicalein    O
,    O
caffeic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
curcumin    O
,    O
hyperforin    O
and    O
St    O
John    O
's    O
wort    O
.    O

An    O
analysis    O
of    O
propolis    O
from    O
Henan    O
,    O
China    O
found    O
sinapinic    O
acid    O
,    O
isoferulic    O
acid    O
,    O
caffeic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
and    O
chrysin    O
,    O
with    O
the    O
first    O
three    O
compounds    O
demonstrating    O
antibacterial    O
properties    O
.    O

Well    O
identified    O
active    O
phytoconstituents    O
includes    O
Gallic    O
acid    O
,    O
Caffeic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
vanillin    O
,    O
p    O
-    O
Coumaric    O
acid    O
.    O

Caffeic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
3,4-Dihydroxycinnamic    O
acid    O
)    O

Phenolics    O
found    O
in    O
flowering    O
heads    O
of    O
"    O
Scorzoneroides    O
"    O
taxa    O
include    O
luteolin    O
type    O
flavonoids    O
and    O
caffeoyl    B-HydroxyAcid114613922
quinic    O
acid    O
derivatives    O
such    O
as    O
chlorogenic    O
acid    O
and    O
3,5-dicaffeoylquinic    O
acid    O
.    O

Phenolics    O
found    O
in    O
"    O
Crepis    O
"    O
include    O
luteolin    O
-    O
type    O
flavonoids    O
and    O
caffeoyl    B-HydroxyAcid114613922
quinic    O
acid    O
derivatives    O
such    O
as    O
chlorogenic    O
acid    O
and    O
3,5-dicaffeoylquinic    O
acid    O
.    O

Moreover    O
,    O
"    O
Crepis    O
"    O
species    O
contain    O
the    O
caffeoyl    B-HydroxyAcid114613922
tartaric    O
acid    O
derivatives    O
caffeoyl    B-HydroxyAcid114613922
tartaric    O
acid    O
and    O
cichoric    O
acid    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
hydroxypyruvate    B-HydroxyAcid114613922
,    O
and    O
one    O
product    O
,    O
2-hydroxy-3-oxopropanoate    O
.    O

Magnesium    O
is    O
absorbed    O
orally    O
at    O
about    O
30%    O
bioavailability    O
from    O
any    O
"    O
water    O
soluble    O
salt    O
,    O
"    O
such    O
as    O
magnesium    O
chloride    O
or    O
magnesium    B-HydroxyAcid114613922
citrate    I-HydroxyAcid114613922
.    O

Magnesium    O
aspartate    O
,    O
chloride    O
,    O
lactate    O
,    O
citrate    B-HydroxyAcid114613922
and    O
glycinate    O
each    O
have    O
bioavailability    O
4    O
times    O
greater    O
than    O
the    O
oxide    O
form    O
and    O
are    O
equivalent    O
to    O
each    O
other    O
per    O
amount    O
of    O
magnesium    O
,    O
though    O
not    O
in    O
price    O
.    O

Magnesium    B-HydroxyAcid114613922
citrate    I-HydroxyAcid114613922
has    O
been    O
reported    O
as    O
more    O
bioavailable    O
than    O
oxide    O
or    O
amino    O
-    O
acid    O
chelate    O
forms    O
.    O

Employing    O
intravascular    O
ultrasound    O
(    O
IVUS    O
)    O
,    O
they    O
showed    O
regression    O
of    O
the    O
atherosclerotic    O
plaques    O
in    O
response    O
to    O
a    O
high    O
dose    O
of    O
rosuvastatin    B-HydroxyAcid114613922

Also    O
,    O
co    O
-    O
administration    O
of    O
eluxadoline    O
with    O
rosuvastatin    B-HydroxyAcid114613922
may    O
increase    O
the    O
risk    O
of    O
rhabdomyolysis    O
.    O

The    O
AURORA    O
trial    O
(    O
A    O
Study    O
to    O
Evaluate    O
the    O
Use    O
of    O
Rosuvastatin    B-HydroxyAcid114613922
in    O
Subjects    O
on    O
Regular    O
Hemodialysis    O
:    O
An    O
Assessment    O
of    O
Survival    O
and    O
Cardiovascular    O
Events    O
)    O
was    O
a    O
randomized    O
,    O
double    O
-    O
blind    O
,    O
placebo    O
-    O
controlled    O
study    O
investigating    O
the    O
use    O
of    O
rosuvastatin    B-HydroxyAcid114613922
in    O
the    O
prevention    O
of    O
cardiovascular    O
disease    O
among    O
patients    O
undergoing    O
chronic    O
hemodialysis    O
.    O

The    O
trial    O
was    O
sponsored    O
,    O
in    O
part    O
,    O
by    O
AstraZeneca    O
,    O
the    O
marketer    O
of    O
Crestor    B-HydroxyAcid114613922
.    O

While    O
a    O
potentially    O
useful    O
antibiotic    O
in    O
its    O
own    O
right    O
,    O
it    O
has    O
now    O
been    O
shown    O
that    O
platensimycin    B-HydroxyAcid114613922
is    O
not    O
specifically    O
active    O
on    O
mtFabH.    O

If    O
the    O
base    O
is    O
off    O
the    O
scale    O
,    O
i.e.    O
a    O
pH    O
of    O
>    O
13.5    O
,    O
and    O
the    O
acid    O
has    O
a    O
pH    O
>    O
5.5    O
,    O
then    O
an    O
Alizarine    B-HydroxyAcid114613922
yellow    I-HydroxyAcid114613922
indicator    O
may    O
be    O
used    O
.    O

It    O
is    O
synthesised    O
from    O
homoisocitrate    B-HydroxyAcid114613922
by    O
aminoadipate    O
aminotransferase    O
and    O
reduced    O
by    O
aminoadipate    O
reductase    O
to    O
form    O
the    O
semialdehyde    O
.    O

The    O
enzyme    O
plays    O
a    O
key    O
role    O
in    O
an    O
alternative    O
pathway    O
of    O
the    O
biosynthesis    O
of    O
3-dehydroquinate    B-HydroxyAcid114613922
.    O

Most    O
"    O
Physaria    O
"    O
species    O
contain    O
the    O
hydroxy    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
lesquerolic    O
acid    O
in    O
their    O
oil    O
with    O
a    O
seed    O
oil    O
content    O
of    O
~24%    O
.    O

Mandelic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
is    O
an    O
aromatic    O
alpha    B-HydroxyAcid114613922
hydroxy    I-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
with    O
the    O
molecular    O
formula    O
C6H5CH(OH)CO2H.    O
It    O
is    O
a    O
white    O
crystalline    O
solid    O
that    O
is    O
soluble    O
in    O
water    O
and    O
polar    O
organic    O
solvents    O
.    O

Alpha    B-HydroxyAcid114613922
hydroxy    I-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
AHAs    O
)    O
are    O
naturally    O
occurring    O
carboxylic    O
acids    O
such    O
as    O
glycolic    O
acid    O
,    O
a    O
natural    O
constituent    O
of    O
sugar    O
cane    O
juice    O
and    O
lactic    O
acid    O
,    O
found    O
in    O
sour    O
milk    O
and    O
tomato    O
juice    O
.    O

They    O
are    O
closely    O
related    O
to    O
alpha    B-HydroxyAcid114613922
hydroxy    I-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
in    O
which    O
the    O
two    O
functional    O
groups    O
are    O
separated    O
by    O
"    O
one    O
"    O
carbon    O
atom    O
.    O

Compared    O
to    O
non    O
-    O
hydroxylated    O
carboxylic    O
acids    O
,    O
this    O
group    O
of    O
acids    O
is    O
stronger    O
,    O
although    O
less    O
strong    O
than    O
the    O
alpha    B-HydroxyAcid114613922
hydroxy    I-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

Within    O
the    O
citric    O
acid    O
cycle    O
,    O
isocitrate    B-HydroxyAcid114613922
,    O
produced    O
from    O
the    O
isomerization    O
of    O
citrate    O
,    O
undergoes    O
both    O
oxidation    O
and    O
decarboxylation    O
.    O

Isocitrate    O
dehydrogenases    O
are    O
enzymes    O
that    O
catalyze    O
the    O
oxidative    O
decarboxylation    O
of    O
isocitrate    B-HydroxyAcid114613922
to    O
2-oxoglutarate    O
.    O

Isocitric    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
caffeoyl    O
-    O
CoA    O
and    O
isocitrate    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
2-caffeoylisocitrate    O
.    O

pamoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Acetolactic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Mutations    O
in    O
the    O
GCDH    O
gene    O
can    O
lead    O
to    O
defects    O
in    O
the    O
enzyme    O
encoded    O
by    O
it    O
which    O
leads    O
to    O
the    O
formation    O
and    O
accumulation    O
of    O
the    O
metabolites    O
glutaric    O
acid    O
and    O
3-hydroxyglutaric    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
as    O
well    O
as    O
glutarylcarnitine    O
in    O
body    O
fluids    O
,    O
which    O
essentially    O
leads    O
to    O
glutaric    O
aciduria    O
type    O
I    O
,    O
an    O
autosomal    O
recessive    O
metabolic    O
disorder    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
propanoyl    O
-    O
CoA    O
,    O
H2O    O
,    O
and    O
glyoxylate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
2-hydroxyglutarate    B-HydroxyAcid114613922
and    O
CoA.    O

Abscisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
ABA    B-HydroxyAcid114613922
)    O
is    O
a    O
plant    O
hormone    O
.    O

The    O
natural    O
ligand    O
of    O
LANCL2    O
,    O
abscisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
ABA    O
)    O
,    O
has    O
been    O
identified    O
as    O
a    O
new    O
endogenous    O
mammalian    O
hormone    O
implicated    O
in    O
glycemic    O
control    O
.    O

Its    O
expression    O
is    O
also    O
increased    O
in    O
response    O
to    O
dehydration    O
,    O
to    O
low    O
temperatures    O
,    O
and    O
to    O
abscisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
and    O
it    O
plays    O
an    O
important    O
role    O
in    O
fruit    O
ripening    O
,    O
seedlings    O
development    O
,    O
and    O
pollen    O
development    O
.    O

Vertebrate    O
grazing    O
is    O
thought    O
to    O
alter    O
plant    O
hormones    O
two    O
of    O
which    O
are    O
known    O
to    O
effect    O
fecundity    O
,    O
abscisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
and    O
gibberellins    O
.    O

ABI3    O
(    O
ABscisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
Insensitive3    O
)    O

Abscisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

They    O
induce    O
changes    O
in    O
gene    O
expression    O
;    O
the    O
production    O
of    O
abscisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
jasmonic    O
acid    O
,    O
and    O
ethylene    O
;    O
temporary    O
decreases    O
in    O
photosynthesis    O
;    O
and    O
increases    O
in    O
respiration    O
.    O

Phaseic    O
acid    O
is    O
a    O
terpenoid    O
catabolite    O
of    O
abscisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

Omega    B-HydroxyAcid114613922
hydroxy    I-HydroxyAcid114613922
acids    I-HydroxyAcid114613922
(    O
also    O
known    O
as    O
ω-hydroxy    O
acids    O
)    O
are    O
a    O
class    O
of    O
naturally    O
occurring    O
straight    O
-    O
chain    O
aliphatic    O
organic    O
acids    O
"    O
n    O
"    O
carbon    O
atoms    O
long    O
with    O
a    O
carboxyl    O
group    O
at    O
position    O
1    O
and    O
a    O
hydroxyl    O
at    O
position    O
"    O
n    O
"    O
.    O

Cyclobutyrol    B-HydroxyAcid114613922
is    O
a    O
drug    O
used    O
in    O
bile    O
therapy    O
.    O

zwitterionic    O
compounds    O
prepared    O
and    O
tested    O
by    O
Good    O
and    O
coworkers    O
for    O
the    O
first    O
time    O
,    O
though    O
some    O
(    O
MES    O
,    O
ADA    O
,    O
BES    O
,    O
Bicine    B-HydroxyAcid114613922
)    O
were    O
known    O
compounds    O
previously    O
overlooked    O
by    O
biologists    O
.    O

3,4-Dihydroxymandelic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
DOMA    O
)    O
→    O
Vanillylmandelic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
VMA    O
)    O

triflusal    B-HydroxyAcid114613922
(    O
INN    O
)    O

For    O
example    O
,    O
the    O
glycolytic    O
intermediate    O
1,3-bisphosphoglyceric    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
has    O
a    O
half    O
-    O
life    O
of    O
27    O
minutes    O
"    O
in    O
vivo    O
"    O
.    O

1,3-Diphosphoglycerate    B-HydroxyAcid114613922

1,3-Diphosphoglyceric    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    O
and    O
3-phospho-D-glycerate    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    O
and    O
3-phospho-D-glyceroyl    B-HydroxyAcid114613922
phosphate    I-HydroxyAcid114613922
.    O

Promoter    O
of    O
the    O
ineffective    O
cancer    O
cures    O
laetrile    O
and    O
pangamic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

12-Hydroxyeicosatetraenoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Finally    O
,    O
cellular    O
peroxidases    O
readily    O
and    O
rapidly    O
reduce    O
12("S")-HpETE    O
to    O
its    O
hydroxyl    O
analog    O
,    O
12"S    O
"-    O
hydroxy-5Z,8Z,10E,14Z    O
-    O
eicosatetraenoic    O
acid    O
(    O
12"S    O
"-    O
HETE    O
;    O
see    O
12-hydroxyeicosatetraenoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
;    O
this    O
reaction    O
competes    O
with    O
the    O
hepoxilin    O
-    O
forming    O
reaction    O
and    O
in    O
cells    O
expressing    O
very    O
high    O
peroxidase    O
activity    O
may    O
be    O
responsible    O
for    O
blocking    O
the    O
formation    O
of    O
the    O
hepoxilins    O
.    O

It    O
is    O
also    O
related    O
(    O
30.4%    O
amino    O
acid    O
sequence    O
identity    O
)    O
to    O
the    O
recently    O
defined    O
receptor    O
,    O
GPR31    O
,    O
for    O
the    O
hydroxyl    O
-    O
carboxy    O
fatty    O
acid    O
12-HETE    B-HydroxyAcid114613922
.    O

"    O
-oxido-5"Z",8"Z",11"Z"-14,15-leukotriene    O
A4    O
as    O
minor    O
products    O
;    O
15("S")-HpETE    O
and    O
12("S")-HpETE    O
are    O
rapidly    O
converted    O
to    O
15("S")-HETE    O
and    O
12("S")-hydroxy-5"Z",8"Z",10"E",15"Z    O
"-    O
eicosatetraenoic    O
acid    O
(    O
12("S")-hydroxyeicosatetraenoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
)    O
,    O
(    O
i.e.    O
12("S")-HETE    O
)    O
,    O
respectively    O
,    O
or    O
further    O
metabolized    O
through    O
other    O
enzyme    O
pathways    O
;    O
14("S"),15("S")-"trans"-    O

This    O
effect    O
could    O
also    O
have    O
anti    O
-    O
inflammatory    O
and    O
anti    O
-    O
oxidative    O
effects    O
by    O
blocking    O
the    O
formation    O
of    O
12-HETE    B-HydroxyAcid114613922
and    O
Hepoxilins    O
.    O

It    O
results    O
in    O
an    O
increase    O
of    O
13-HODE    O
and    O
decrease    O
of    O
12-HETE    B-HydroxyAcid114613922
in    O
the    O
subendothelial    O
matrix    O
(    O
SEM    O
)    O
and    O
reduced    O
thrombogenicity    O
of    O
the    O
SEM    O
.    O

5-ASA    O
compounds    O
,    O
such    O
as    O
mesalazine    B-HydroxyAcid114613922
and    O
sulfasalazine    B-HydroxyAcid114613922
,    O
have    O
shown    O
to    O
be    O
of    O
very    O
little    O
efficacy    O
in    O
the    O
treatment    O
of    O
Crohn    O
's    O
disease    O
,    O
either    O
for    O
induction    O
or    O
for    O
maintenance    O
of    O
remission    O
.    O

Additional    O
treatments    O
include    O
retinoids    O
,    O
such    O
as    O
acitretin    O
,    O
or    O
sulfasalazine    B-HydroxyAcid114613922
.    O

Mesalazine    O
is    O
the    O
active    O
moiety    O
of    O
sulfasalazine    B-HydroxyAcid114613922
,    O
which    O
is    O
metabolized    O
to    O
sulfapyridine    O
and    O
mesalazine    O
.    O

It    O
has    O
also    O
been    O
used    O
as    O
a    O
second    O
line    O
agent    O
to    O
sulfasalazine    B-HydroxyAcid114613922
in    O
people    O
with    O
inflammatory    O
bowel    O
disease    O
such    O
as    O
ulcerative    O
colitis    O
and    O
Crohn    O
's    O
disease    O
.    O

PAS    O
has    O
also    O
been    O
used    O
in    O
the    O
treatment    O
of    O
inflammatory    O
bowel    O
disease    O
(    O
ulcerative    O
colitis    O
and    O
Crohn    O
's    O
disease    O
)    O
,    O
but    O
has    O
been    O
superseded    O
by    O
other    O
drugs    O
such    O
as    O
sulfasalazine    B-HydroxyAcid114613922
and    O
mesalazine    B-HydroxyAcid114613922
.    O

Xanthurenic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

6-Phosphogluconic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
6-phosphogluconate    B-HydroxyAcid114613922
)    O
is    O
an    O
intermediate    O
in    O
the    O
pentose    O
phosphate    O
pathway    O
and    O
the    O
Entner–    O

HPPD    O
also    O
catalyzes    O
the    O
conversion    O
of    O
phenylpyruvate    O
to    O
2-hydroxyphenylacetate    O
and    O
the    O
conversion    O
of    O
α-ketoisocaproate    O
to    O
β-hydroxy    B-HydroxyAcid114613922
β-methylbutyrate    I-HydroxyAcid114613922
.    O

Human    O
metabolic    O
pathway    O
for    O
β-hydroxy    B-HydroxyAcid114613922
β-methylbutyric    I-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
HMB    O
)    O
and    O
isovaleryl    O
-    O
CoA    O
,    O
relative    O
to    O
leucine    O
.    O

β-Hydroxy    B-HydroxyAcid114613922
β-methylbutyric    I-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

It    O
is    O
a    O
molecule    O
having    O
a    O
hexahydroxydiphenic    O
acid    O
group    O
and    O
two    O
gallic    O
acids    O
attached    O
to    O
a    O
gluconic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
core    O
.    O

Members    O
of    O
the    O
GntP    O
family    O
include    O
known    O
gluconate    B-HydroxyAcid114613922
permeases    O
of    O
"    O
E.    O
coli    O
"    O
and    O
"    O
Bacillus    O
"    O
species    O
such    O
as    O
the    O
D    O
-    O
Gluconate    O
:    O
H+    O
symporter    O
of    O
"    O
Bacillus    O
subtillus    O
"    O
(    O
GntP    O
;    O
TC    O
#    O
2.A.8.1.1    O
)    O
and    O
the    O
D    O
-    O
fructuronate    O
/    O
D    O
-    O
gluconate    O
:    O
H+    O
symporter    O
of    O
"    O
E.    O
coli    O
"    O
(    O
GntP    O
;    O
TC    O
#    O
2.A.8.1.3    O
)    O
.    O

Emil    O
Fischer    O
establishes    O
the    O
stereochemistry    O
and    O
isomeric    O
nature    O
of    O
the    O
sugars    O
by    O
epimerization    O
between    O
gluconic    B-HydroxyAcid114613922
and    O
mannonic    O
acids    O
and    O
synthesizes    O
glucose    O
,    O
fructose    O
and    O
mannose    O
from    O
glycerol    O
.    O

A    O
complete    O
list    O
of    O
the    O
ingredients    O
includes    O
:    O
soybean    O
oil    O
,    O
water    O
,    O
egg    O
yolk    O
,    O
gluconic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
yeast    O
extract    O
,    O
stabilizer    O
(    O
microcrystalline    O
cellulose    O
,    O
modified    O
food    O
starch    O
,    O
xanthan    O
gum    O
,    O
guar    O
gum    O
,    O
gum    O
arabic    O
)    O
,    O
cultured    O
dextrose    O
,    O
salt    O
,    O
sugar    O
,    O
dehydrated    O
garlic    O
,    O
paprika    O
,    O
dehydrated    O
onion    O
,    O
spice    O
,    O
natural    O
smoke    O
flavor    O
,    O
natural    O
flavors    O
,    O
tocopherols    O
,    O
calcium    O
disodium    O
EDTA    O
,    O
and    O
autolyzed    O
yeast    O
extract    O
.    O

It    O
is    O
a    O
lactone    O
of    O
D    O
-    O
gluconic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D-gluconate    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
6-phospho    O
-    O
D    O
-    O
gluconate    O
.    O

While    O
effective    O
,    O
these    O
agents    O
are    O
now    O
known    O
to    O
have    O
serious    O
environmental    O
consequences    O
leading    O
to    O
a    O
drive    O
towards    O
more    O
environmentally    O
benign    O
phosphorus    O
-    O
free    O
agents    O
,    O
modern    O
examples    O
include    O
chelators    O
such    O
as    O
citric    O
acid    O
,    O
gluconic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
and    O
EDTA    O
;    O
or    O
ion    O
exchange    O
agents    O
like    O
zeolites    O
.    O

A    O
mixture    O
of    O
5-methoxysalicylic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
and    O
spermine    O
can    O
be    O
used    O
as    O
a    O
matrix    O
for    O
oligonucleotides    O
analysis    O
in    O
MALDI    O
mass    O
spectrometry    O
.    O

2-Hydroxyisocaproic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

The    O
five    O
-    O
carbon    O
ketones    O
produced    O
from    O
triheptanoin    O
are    O
beta    O
-    O
ketopentanoate    O
and    O
beta-hydroxypentanoate    B-HydroxyAcid114613922
.    O

etalocib    B-HydroxyAcid114613922
(    O
USAN    O
)    O

4-Hydroxyphenylacetic    O
acid    O
is    O
obtained    O
by    O
reducing    O
4-hydroxymandelic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
with    O
elemental    O
phosphorus    O
and    O
iodine    O
.    O

The    O
three    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
,    O
3-methyl-2-oxobutanoate    O
,    O
and    O
H2O    O
,    O
and    O
its    O
products    O
are    O
(2S)-2-isopropylmalate    B-HydroxyAcid114613922
and    O
CoA.    O

Sharpless    O
epoxidation    O
of    O
allyl    O
alcohols    O
using    O
titanium    O
isopropoxide    O
,    O
diethyl    B-HydroxyAcid114613922
tartrate    I-HydroxyAcid114613922
,    O
and    O
"    O
tert    O
"-    O
butyl    O
hydroxyperoxide    O

Myrmicacin    B-HydroxyAcid114613922

4-Aminosalicylic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
an    O
antibiotic    O
sold    O
by    O
Jacobus    O
Pharmaceutical    O
under    O
the    O
trademark    O
"    O
Paser    O
"    O

4-Aminosalicylic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
also    O
known    O
as    O
para"-    O

aminosalicylic    O
acid    O
("'PAS    B-HydroxyAcid114613922
)    O
is    O
an    O
antibiotic    O
primarily    O
used    O
to    O
treat    O
tuberculosis    O
.    O

4-Hydroxy-4-methylpentanoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
UMB68    B-HydroxyAcid114613922
)    O
is    O
a    O
tertiary    O
alcohol    O
,    O
similar    O
in    O
structure    O
to    O
the    O
drug    O
GHB    O
.    O

3-Phosphoglycerate    B-HydroxyAcid114613922

3-Phosphoglyceric    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
(    O
R)-glycerate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
either    O
3-phospho-(R)-glycerate    B-HydroxyAcid114613922
or    O
2-phospho-(R)-glycerate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    O
and    O
3-phospho-D-glycerate    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    O
and    O
3-phospho-D-glyceroyl    B-HydroxyAcid114613922
phosphate    I-HydroxyAcid114613922
.    O

Glycerate    B-HydroxyAcid114613922
3-phosphate    I-HydroxyAcid114613922
,    O
a    O
3-carbon    O
molecule    O

The    O
occurrence    O
of    O
photorespiration    O
in    O
plants    O
,    O
due    O
to    O
the    O
lack    O
of    O
substrate    O
specificity    O
of    O
rubisco    O
,    O
leads    O
to    O
the    O
formation    O
of    O
2-phosphoglycolate    O
and    O
3-phosphogylcerate    B-HydroxyAcid114613922
)    O
.    O

In    O
both    O
pathways    O
3-phosphoglycerate    B-HydroxyAcid114613922
(    O
3-PGA    O
or    O
3-PG    O
)    O
is    O
reduced    O
to    O
fructose    O
1,6-bisphosphate    O
with    O
aldolase    O
catalyzing    O
the    O
last    O
reaction    O
.    O

:    O
3-PG    B-HydroxyAcid114613922
+    O
NADPH    O
+    O
H+    O
+    O
ATP    O
+    O
H2O    O
)    O
fructose    O
1,6-bisphosphate    O
+    O
2(NADP+    O
+    O
ADP    O
+    O
Pi    O
)    O

Some    O
combination    O
of    O
miltefosine    O
,    O
paramycin    B-HydroxyAcid114613922
and    O
liposomal    O
amphotericin    O
B    O
,    O
however    O
,    O
may    O
be    O
recommended    O
due    O
to    O
issues    O
with    O
resistance    O
.    O

Aminosalicylic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

3-Hydroxypropionic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
hydracrylic    O
acid    O
)    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
3-hydroxy-2-methylpropanoyl    O
-    O
CoA    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
3-hydroxy-2-methylpropanoate    B-HydroxyAcid114613922
.    O

Examples    O
of    O
resin    O
acids    O
are    O
abietic    O
acid    O
(    O
sylvic    O
acid    O
)    O
,    O
C20H30O2    O
,    O
plicatic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
contained    O
in    O
cedar    O
,    O
and    O
pimaric    O
acid    O
,    O
C20H30O2    O
,    O
a    O
constituent    O
of    O
galipot    O
resin    O
.    O

2-Hydroxybutyric    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
also    O
known    O
as    O
alpha    O
"-    O
hydroxybutyrate    O
and    B-HydroxyAcid114613922
"'α-hydroxybutyrate    I-HydroxyAcid114613922
,    O
is    O
a    O
hydroxybutyric    O
acid    O
with    O
the    O
hydroxyl    O
group    O
on    O
the    O
carbon    O
adjacent    O
to    O
the    O
carboxyl    O
.    O

Salsalate    B-HydroxyAcid114613922

Salsalate    B-HydroxyAcid114613922
is    O
a    O
medication    O
that    O
belongs    O
to    O
the    O
salicylate    O
and    O
nonsteroidal    O
anti    O
-    O
inflammatory    O
drug    O
(    O
NSAID    O
)    O
classes    O
.    O

Homogentisic    O
acid    O
(    O
2,5-dihydroxyphenylacetic    O
acid    O
)    O
is    O
a    O
phenolic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
usually    O
found    O
in    O
"    O
Arbutus    O
unedo    O
"    O
(    O
strawberry    O
-    O
tree    O
)    O
honey    O
.    O

"    O
lipase    O
can    O
be    O
used    O
to    O
catalyze    O
the    O
regioselective    O
acylation    O
of    O
flavonoids    O
or    O
the    O
direct    O
acetylation    O
with    O
phenolic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

As    O
an    O
unpigmented    O
fruit    O
flesh    O
,    O
rambutan    O
does    O
not    O
contain    O
significant    O
polyphenol    O
content    O
,    O
but    O
its    O
colorful    O
rind    O
displays    O
diverse    O
phenolic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
such    O
as    O
syringic    O
,    O
coumaric    O
,    O
gallic    O
,    O
caffeic    B-HydroxyAcid114613922
,    O
and    O
ellagic    O
acids    O
having    O
antioxidant    O
activity    O
in    O
vitro    O
.    O

Pentahydroxybenzoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Phenolic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Flavonols    O
were    O
found    O
to    O
be    O
the    O
predominating    O
class    O
of    O
phenolic    O
compounds    O
while    O
phenolic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
and    O
flavan-3-ols    O
(    O
"    O
catechins    O
"    O
)    O
represent    O
minor    O
components    O
.    O

It    O
is    O
also    O
used    O
as    O
a    O
source    O
of    O
flavonoids    O
,    O
catechins    O
,    O
proanthocyanidins    O
,    O
and    O
phenolic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

First    O
synthesis    O
of    O
tropic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
in    O
1880    O
,    O
together    O
with    O
Albert    O
Ladenburg    O
.    O

It    O
is    O
produced    O
when    O
3,5-dinitrosalicylic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
reacts    O
with    O
a    O
reducing    O
sugar    O
.    O

Small    O
amounts    O
of    O
salicylic    O
acid    O
are    O
also    O
hydroxylated    O
to    O
gentisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

Salicylates    O
are    O
excreted    O
mainly    O
by    O
the    O
kidneys    O
as    O
salicyluric    O
acid    O
(    O
75%    O
)    O
,    O
free    O
salicylic    O
acid    O
(    O
10%    O
)    O
,    O
salicylic    O
phenol    O
(    O
10%    O
)    O
,    O
and    O
acyl    O
glucuronides    O
(    O
5%    O
)    O
,    O
gentisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
<    O
1%    O
)    O
,    O
and    O
2,3-dihydroxybenzoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

The    O
shikimate    O
pathway    O
is    O
a    O
biosynthetic    O
pathways    O
that    O
uses    O
the    O
starting    O
materials    O
Phosphoenolpyruvic    O
acid    O
(    O
PEP    O
)    O
and    O
Erythrose    O
4-phosphate    O
to    O
form    O
shikimic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
which    O
then    O
further    O
reacts    O
to    O
form    O
specific    O
aromatic    O
amino    O
acids    O
.    O

Plants    O
and    O
microorganisms    O
commonly    O
synthesize    O
tryptophan    O
from    O
shikimic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
or    O
anthranilate    O
:    O
anthranilate    O
condenses    O
with    O
phosphoribosylpyrophosphate    O
(    O
PRPP    O
)    O
,    O
generating    O
pyrophosphate    O
as    O
a    O
by    O
-    O
product    O
.    O

Most    O
members    O
of    O
the    O
Boletales    O
are    O
characterized    O
by    O
compounds    O
produced    O
by    O
the    O
shikimate    B-HydroxyAcid114613922
-    O
chorismate    O
pathway    O
,    O
including    O
several    O
distinctive    O
pigments    O
.    O

Phenazine    O
biosynthesis    O
branches    O
off    O
the    O
shikimic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
pathway    I-HydroxyAcid114613922
at    O
a    O
point    O
subsequent    O
to    O
chorismic    O
acid    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
4-coumaroyl    O
-    O
CoA    O
and    O
shikimate    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
4-coumaroylshikimate    O
.    O

Shikimate    O
kinase    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
ATP    O
-    O
dependent    O
phosphorylation    O
of    O
shikimate    B-HydroxyAcid114613922
to    O
form    O
shikimate    O
3-phosphate    O
.    O

Shikimate    O
kinase    O
thus    O
has    O
two    O
substrates    O
,    O
shikimate    B-HydroxyAcid114613922
and    O
ATP    O
,    O
and    O
two    O
products    O
,    O
shikimate    O
3-phosphate    O
and    O
ADP    O
.    O

Maximiscin    O
is    O
a    O
polyketide    O
-    O
shikimate    B-HydroxyAcid114613922
isolate    O
of    O
"    O
Tolypocladium    O
"    O
with    O
anticancer    O
activity    O
.    O

The    O
product    O
can    O
be    O
obtained    O
also    O
by    O
oxidation    O
of    O
tartronic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Sulfosalicylic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Dipentum    B-HydroxyAcid114613922

At    O
harvest    O
the    O
grapes    O
usually    O
have    O
a    O
high    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
and    O
high    O
levels    O
of    O
aromatic    O
phenolic    O
compounds    O
such    O
as    O
terpenes    O
that    O
contribute    O
floral    O
,    O
tropical    O
and    O
citrus    O
notes    O
to    O
the    O
wine    O
.    O

RuBisCO    O
only    O
operates    O
during    O
the    O
day    O
,    O
when    O
stomata    O
are    O
sealed    O
and    O
is    O
provided    O
by    O
the    O
breakdown    O
of    O
the    O
chemical    O
malate    B-HydroxyAcid114613922
.    O

A    O
principal    O
route    O
is    O
upon    O
oxidation    O
of    O
L    O
-    O
malate    B-HydroxyAcid114613922
,    O
catalysed    O
by    O
malate    O
dehydrogenase    O
,    O
in    O
the    O
citric    O
acid    O
cycle    O
.    O

NADH    O
reduces    O
oxaloacetate    O
to    O
malate    B-HydroxyAcid114613922
.    O

Fumarate    O
can    O
be    O
transformed    O
into    O
malate    B-HydroxyAcid114613922
by    O
the    O
actions    O
of    O
the    O
enzyme    O
fumarase    O
.    O

Also    O
compared    O
to    O
Cabernet    O
,    O
Merlot    O
grapes    O
tend    O
to    O
have    O
a    O
higher    O
sugar    O
content    O
and    O
lower    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

Additionally    O
,    O
SGCs    O
contain    O
the    O
glutamate    O
related    O
enzymes    O
glutamate    O
dehydrogenase    O
and    O
pyruvate    O
carboxylase    O
,    O
and    O
thus    O
can    O
supply    O
the    O
neurons    O
not    O
only    O
with    O
glutamine    O
,    O
but    O
also    O
with    O
malate    B-HydroxyAcid114613922
and    O
lactate    O
.    O

Acids    O
in    O
wine    O
:    O
tartaric    O
,    O
malic    B-HydroxyAcid114613922
and    O
citric    O
are    O
the    O
principal    O
acids    O
in    O
wine    O
.    O

Flesh    O
thin    O
and    O
sour    O
,    O
charged    O
with    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
;    O
seeds    O
light    O
brown    O
,    O
oblong    O
,    O
compressed    O
;    O
cotyledons    O
fleshy    O
.    O

Malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
an    O
organic    O
compound    O

The    O
reaction    O
was    O
first    O
published    O
by    O
G.    O
Fráter    O
in    O
1979    O
;    O
in    O
1980    O
,    O
Dieter    O
Seebach    O
reported    O
about    O
a    O
similar    O
reaction    O
with    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
ester    O
.    O

There    O
are    O
five    O
usual    O
fruit    O
acids    O
:    O
citric    O
acid    O
,    O
glycolic    O
acid    O
,    O
lactic    O
acid    O
,    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
and    O
tartaric    O
acid    O
.    O

Malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Sodium    O
fluoride    O
/    O
malic    O
acid    O
(    O
trade    O
name    O
Xerodent    O
)    O
is    O
a    O
type    O
of    O
mouthwash    O
consisting    O
of    O
the    O
teeth    O
-    O
strengthening    O
sodium    O
fluoride    O
and    O
the    O
saliva    O
stimulant    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
,    O
H2O    O
,    O
and    O
glyoxylate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
(S)-malate    B-HydroxyAcid114613922
and    O
CoA.    O

The    O
enzyme    O
is    O
free    O
to    O
release    O
the    O
malate    B-HydroxyAcid114613922
and    O
the    O
coenzyme    O
A    O
molecules    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
1-O    O
-    O
sinapoyl    O
-    O
beta    O
-    O
D    O
-    O
glucose    O
and    O
(S)-malate    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
D    O
-    O
glucose    O
and    O
sinapoyl-(S)-malate    O
.    O

As    O
such    O
OAA    O
is    O
converted    O
into    O
malate    B-HydroxyAcid114613922
by    O
mitochondrial    O
Malate    O
dehydrogenase    O
(    O
MDH    O
)    O
.    O

A    O
study    O
of    O
the    O
antioxidant    O
capacity    O
of    O
the    O
mushroom    O
was    O
composed    O
of    O
at    O
least    O
five    O
organic    O
acids    O
:    O
oxalic    O
,    O
citric    O
,    O
malic    B-HydroxyAcid114613922
,    O
quinic    O
,    O
and    O
fumaric    O
acids    O
.    O

The    O
drug    O
,    O
along    O
with    O
gum    O
,    O
fatty    O
oils    O
,    O
and    O
malate    B-HydroxyAcid114613922
of    O
magnesium    O
and    O
calcium    O
,    O
contains    O
also    O
about    O
1%    O
of    O
cubebic    O
acid    O
,    O
and    O
about    O
6%    O
of    O
a    O
resin    O
.    O

Typical    O
sourness    O
of    O
the    O
fruits    O
is    O
due    O
to    O
high    O
content    O
of    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
0.8    O
-    O
3.2    O
g/100    O
ml    O
of    O
juice    O
)    O
while    O
astringency    O
is    O
related    O
to    O
quinic    O
acid    O
(    O
1.2    O
-    O
2.1    O
g/100    O
ml    O
of    O
juice    O
)    O
.    O

To    O
avoid    O
legal    O
issues    O
with    O
the    O
Mineralbrunnen    O
AG    O
,    O
one    O
ingredient    O
had    O
to    O
be    O
changed    O
later    O
in    O
2004    O
:    O
phosphoric    O
acid    O
instead    O
of    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

As    O
assumed    O
by    O
its    O
name    O
,    O
"    O
Desulfobulbus    O
"    O
"    O
propionicus    O
"    O
reduces    O
sulfate    O
,    O
sulfite    O
,    O
and    O
thiosulfate    O
to    O
hydrogen    O
sulfide    O
(    O
H2S    O
)    O
,    O
but    O
does    O
not    O
reduce    O
elemental    O
sulfur    O
,    O
malate    B-HydroxyAcid114613922
,    O
and    O
fumarate    O
.    O

To    O
circumvent    O
this    O
,    O
malate    B-HydroxyAcid114613922
carries    O
the    O
reducing    O
equivalents    O
across    O
the    O
membrane    O
.    O

malate    B-HydroxyAcid114613922
-    O
alpha    O
-    O
ketoglutarate    O
antiporter    O
in    O
the    O
inner    O
membrane    O
.    O

Malolactic    O
fermentation    O
(    O
also    O
known    O
as    O
malolactic    O
conversion    O
or    O
MLF    O
)    O
is    O
a    O
process    O
in    O
winemaking    O
in    O
which    O
tart    O
-    O
tasting    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
naturally    O
present    O
in    O
grape    O
must    O
,    O
is    O
converted    O
to    O
softer    O
-    O
tasting    O
lactic    O
acid    O
.    O

Fruits    O
that    O
are    O
high    O
in    O
sugar    O
and    O
acidity    O
(    O
such    O
as    O
the    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
in    O
green    O
apples    O
)    O
can    O
make    O
wines    O
taste    O
metallic    O
and    O
thin    O
bodied    O
.    O

Instead    O
of    O
transferring    O
the    O
generated    O
NADH    O
,    O
a    O
malate    O
dehydrogenase    O
enzyme    O
converts    O
oxaloacetate    O
to    O
malate    B-HydroxyAcid114613922
,    O
which    O
is    O
translocated    O
to    O
the    O
mitochondrial    O
matrix    O
.    O

All    O
parts    O
of    O
the    O
plant    O
contain    O
slightly    O
poisonous    O
oxalic    O
acid    O
,    O
but    O
its    O
concentration    O
in    O
the    O
leaf    O
stems    O
or    O
petioles    O
used    O
in    O
food    O
preparation    O
is    O
very    O
low    O
,    O
and    O
their    O
tart    O
flavor    O
instead    O
is    O
caused    O
by    O
nontoxic    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

They    O
are    O
also    O
mildly    O
tart    O
and    O
tangy    O
in    O
flavor    O
,    O
due    O
to    O
citric    O
acid    O
and    O
malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
which    O
are    O
sometimes    O
crystals    O
that    O
coat    O
the    O
sweets    O
.    O

Malic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
ascorbic    O
acid    O
,    O
citric    O
acid    O
,    O
ketoglutaric    O
acid    O
,    O
fumaric    O
acid    O
,    O
shikimic    O
acid    O
and    O
traces    O
of    O
succinic    O
acid    O
were    O
detected    O
.    O

3-Amino-5-nitrosalicylic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
is    O
an    O
aromatic    O
compound    O
that    O
absorbs    O
light    O
strongly    O
at    O
540    O
nm    O
.    O

Dimenoxadol    O
(    O
INN    O
)    O
(    O
brand    O
name    O
Estocin    O
(    O
in    O
Russia    O
)    O
)    O
,    O
or    O
dimenoxadole    O
(    O
BAN    O
)    O
,    O
is    O
an    O
opioid    O
analgesic    O
which    O
is    O
a    O
benzilic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
derivative    O
,    O
closely    O
related    O
to    O
benactyzine    O
(    O
an    O
anticholinergic    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
and    O
L-homoserine    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
O    O
-    O
acetyl    O
-    O
L    O
-    O
homoserine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
succinyl    O
-    O
CoA    O
and    O
L-homoserine    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
O    O
-    O
succinyl    O
-    O
L    O
-    O
homoserine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
L-homoserine    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
O    O
-    O
phospho    O
-    O
L    O
-    O
homoserine    O
.    O

Secondary    O
metabolites    O
include    O
arthothelin    O
,    O
isoarthothelin    O
,    O
6-O    O
-    O
methylarthothelin    O
,    O
4    O
,    O
5-dichloronorlichexanthone    O
,    O
4    O
,    O
5-dichloro-6-O    O
-    O
methylnorlichexanthone    O
,    O
asemone    O
,    O
thiophanic    O
acid    O
,    O
gyrophoric    O
acid    O
,    O
lecanoric    O
acid    O
,    O
and    O
orsellinic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
,    O
H2O    O
,    O
and    O
2-oxoglutarate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
(R)-2-hydroxybutane-1,2,4-tricarboxylate    B-HydroxyAcid114613922
and    O
CoA.    O

Recent    O
studies    O
have    O
found    O
that    O
great    O
mullein    O
contains    O
glycyrrhizin    B-HydroxyAcid114613922
compounds    O
with    O
bactericide    O
and    O
potential    O
anti    O
-    O
tumoral    O
action    O
.    O

This    O
deficiency    O
—    O
known    O
as    O
apparent    O
mineralocorticoid    O
excess    O
syndrome    O
—    O
can    O
either    O
be    O
congenital    O
or    O
caused    O
by    O
consumption    O
of    O
glycyrrhizin    B-HydroxyAcid114613922
,    O
which    O
is    O
contained    O
in    O
extract    O
of    O
licorice    O
,    O
sometimes    O
found    O
in    O
herbal    O
supplements    O
,    O
candies    O
,    O
and    O
chewing    O
tobacco    O
.    O

Glycyrrhizin    B-HydroxyAcid114613922

Together    O
these    O
plants    O
are    O
used    O
to    O
create    O
a    O
drink    O
containing    O
puerarin    O
,    O
daidzein    O
,    O
paenoflorin    O
,    O
cinnamic    O
acid    O
,    O
glycyrrhizin    B-HydroxyAcid114613922
,    O
ephedrine    O
and    O
gingerol    O
.    O

It    O
contains    O
the    O
chemical    O
glycyrrhizin    B-HydroxyAcid114613922
,    O
which    O
has    O
medicinal    O
uses    O
,    O
but    O
at    O
higher    O
levels    O
it    O
can    O
be    O
toxic    O
.    O

Knock    O
-    O
down    O
research    O
in    O
respiratory    O
epithelium    O
using    O
CerS5    O
siRNA    O
or    O
fumonisin    B-HydroxyAcid114613922
B1    I-HydroxyAcid114613922
reduced    O
total    O
CerS    O
activity    O
by    O
45%    O
or    O
78%    O
,    O
respectively    O
,    O
indicating    O
that    O
CerS5    O
indeed    O
contributes    O
significantly    O
to    O
ceramide    O
synthesis    O
in    O
lung    O
.    O

Fumonisins    O
–    O
Crop    O
corn    O
can    O
be    O
easily    O
contaminated    O
by    O
the    O
fungi    O
Fusarium    O
moniliforme    O
,    O
and    O
its    O
Fumonisin    B-HydroxyAcid114613922
B1    I-HydroxyAcid114613922
will    O
cause    O
Leukoencephalomalacia    O
(    O
LEM    O
)    O
in    O
horses    O
,    O
Pulmonary    O
edema    O
syndrome    O
(    O
PES    O
)    O
in    O
pigs    O
,    O
liver    O
cancer    O
in    O
rats    O
and    O
Esophageal    O
cancer    O
in    O
humans    O
.    O

"gamma"-Hydroxyvaleric    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

3,10-Dihydroxydecanoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

2,3-Dihydroxy-3-methylpentanoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
is    O
an    O
intermediate    O
in    O
the    O
metabolism    O
of    O
isoleucine    O
.    O

4-Methylsalicylic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
otherwise    O
known    O
as    O
2-Hydroxy-4-methylbenzoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
is    O
a    O
chemical    O
compound    O
.    O

Treatment    O
initially    O
involves    O
the    O
use    O
of    O
medications    O
to    O
eliminate    O
infections    O
(    O
generally    O
antibiotics    O
)    O
and    O
reduce    O
inflammation    O
(    O
generally    O
aminosalicylate    B-HydroxyAcid114613922
anti    O
-    O
inflammatory    O
drugs    O
and    O
corticosteroids    O
)    O
.    O

5-ASA    O
compounds    O
,    O
such    O
as    O
mesalazine    B-HydroxyAcid114613922
and    O
sulfasalazine    B-HydroxyAcid114613922
,    O
have    O
shown    O
to    O
be    O
of    O
very    O
little    O
efficacy    O
in    O
the    O
treatment    O
of    O
Crohn    O
's    O
disease    O
,    O
either    O
for    O
induction    O
or    O
for    O
maintenance    O
of    O
remission    O
.    O

Mesalazine    B-HydroxyAcid114613922

Mesalazine    B-HydroxyAcid114613922
(    O
INN    O
,    O
BAN    O
)    O
,    O
also    O
known    O
as    O
mesalamine    B-HydroxyAcid114613922
(    O
USAN    O
)    O
or    O
5-aminosalicylic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
5-ASA    B-HydroxyAcid114613922
)    O
,    O
is    O
an    O
aminosalicylate    O
anti    O
-    O
inflammatory    O
drug    O
used    O
to    O
treat    O
inflammatory    O
bowel    O
disease    O
,    O
including    O
ulcerative    O
colitis    O
,    O
or    O
inflamed    O
anus    O
or    O
rectum    O
,    O
and    O
to    O
maintain    O
remission    O
in    O
Crohn    O
's    O
disease    O
.    O

PAS    O
has    O
also    O
been    O
used    O
in    O
the    O
treatment    O
of    O
inflammatory    O
bowel    O
disease    O
(    O
ulcerative    O
colitis    O
and    O
Crohn    O
's    O
disease    O
)    O
,    O
but    O
has    O
been    O
superseded    O
by    O
other    O
drugs    O
such    O
as    O
sulfasalazine    B-HydroxyAcid114613922
and    O
mesalazine    B-HydroxyAcid114613922
.    O

The    O
2-"C    O
"-    O
methyl    O
-    O
D    O
-    O
erythritol    O
4-phosphate/1-deoxy    O
-    O
D    O
-    O
xylulose    O
5-phosphate    O
pathway    O
(    O
MEP    O
/    O
DOXP    O
pathway    O
)    O
,    O
also    O
known    O
as    O
[    O
non    O
-    O
mevalonate    O
pathway    O
]    O
or    O
mevalonic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
-    O
independent    O
pathway    O
,    O
takes    O
place    O
in    O
the    O
plastids    O
of    O
plants    O
and    O
apicomplexan    O
protozoa    O
,    O
as    O
well    O
as    O
in    O
many    O
bacteria    O
.    O

IPP    O
is    O
formed    O
from    O
acetyl    O
-    O
CoA    O
via    O
the    O
intermediacy    O
of    O
mevalonic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
in    O
the    O
HMG    O
-    O
CoA    O
reductase    O
pathway    O
.    O

Mevalonate    B-HydroxyAcid114613922
is    O
a    O
key    O
intermediate    O
,    O
and    O
mevalonate    O
kinase    O
a    O
key    O
early    O
enzyme    O
,    O
in    O
isoprenoid    O
and    O
sterol    O
synthesis    O
.    O

Mevalonic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

ATP    O
+    O
"    O
(    O
mevalonate    B-HydroxyAcid114613922
ADP    O
+    O
"    O
(    O
R)"-5-phosphomevalonate    O
.    O

Mevalonic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Cholesterol    O
is    O
bio    O
-    O
synthesised    O
from    O
mevalonate    B-HydroxyAcid114613922
via    O
a    O
squalene    O
cyclisation    O
of    O
terpenoids    O
.    O

"    O
Ginkgo    O
biloba    O
"    O
leaves    O
and    O
sarcotesta    O
also    O
contain    O
ginkgolic    O
acids    O
,    O
which    O
are    O
highly    O
allergenic    O
,    O
long    O
-    O
chain    O
alkylphenols    O
such    O
as    O
bilobol    O
or    O
adipostatin    O
A    O
(    O
bilobol    O
is    O
a    O
substance    O
related    O
to    O
anacardic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
from    O
cashew    O
nut    O
shells    O
and    O
urushiols    O
present    O
in    O
poison    O
ivy    O
and    O
other    O
"    O
Toxicodendron    O
"    O
spp    O
.    O
)    O
Individuals    O
with    O
a    O
history    O
of    O
strong    O
allergic    O
reactions    O
to    O
poison    O
ivy    O
,    O
mangoes    O
,    O
cashews    O
and    O
other    O
alkylphenol    O
-    O
producing    O
plants    O
are    O
more    O
likely    O
to    O
experience    O
allergic    O
reaction    O
when    O
consuming    O
non    O
-    O
standardized    O
ginkgo    O
-    O
containing    O
preparations    O
,    O
combinations    O
,    O
or    O
extracts    O
thereof    O
.    O

Anacardic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Like    O
amphotericin    O
B    O
and    O
natamycin    B-HydroxyAcid114613922
,    O
nystatin    O
binds    O
to    O
ergosterol    O
,    O
a    O
major    O
component    O
of    O
the    O
fungal    O
cell    O
membrane    O
.    O

Typical    O
therapy    O
includes    O
administration    O
of    O
natamycin    B-HydroxyAcid114613922
and    O
azoles    O
such    O
as    O
intraconazol    O
,    O
fluconazol    O
,    O
posaconazole    O
and    O
voriconazole    O
.    O

Streptomyces    O
lydicus    O
"    O
produces    O
actithiazic    O
acid    O
,    O
natamycin    B-HydroxyAcid114613922
,    O
lydimycin    O
,    O
streptolydigin    O
,    O
and    O
1-deoxygalactonojirimycin    O
.    O

For    O
the    O
treatment    O
for    O
filamentous    O
fungal    O
keratitis    O
,    O
"    O
topical    O
natamycin    B-HydroxyAcid114613922
is    O
usually    O
the    O
first    O
choice    O
.    O
"    O

Seven    O
phenolic    O
compounds    O
,    O
including    O
ferulic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
vanillic    O
acid    O
,    O
coumaric    O
acid    O
,    O
syringic    O
acid    O
,    O
myricetin    O
,    O
and    O
juglone    O
were    O
identified    O
in    O
walnut    O
husks    O
.    O

Streptomyces    O
olivochromogenes    O
is    O
a    O
bacterium    O
species    O
from    O
the    O
genus    O
of    O
"    O
Streptomyces    O
"    O
which    O
has    O
been    O
isolated    O
from    O
soil."Streptomyces    O
olivochromogenes    O
"    O
produces    O
ferulic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

The    O
oil    O
compartments    O
in    O
açaí    O
fruit    O
contain    O
polyphenols    O
such    O
as    O
procyanidin    O
oligomers    O
and    O
vanillic    O
acid    O
,    O
syringic    O
acid    O
,    O
p    O
-    O
hydroxybenzoic    O
acid    O
,    O
protocatechuic    O
acid    O
,    O
and    O
ferulic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
which    O
were    O
shown    O
to    O
degrade    O
substantially    O
during    O
storage    O
or    O
exposure    O
to    O
heat    O
.    O

Cinnamic    O
acid    O
and    O
its    O
derivatives    O
,    O
such    O
as    O
ferulic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
-    O
found    O
in    O
seeds    O
of    O
plants    O
such    O
as    O
in    O
brown    O
rice    O
,    O
whole    O
wheat    O
and    O
oats    O
,    O
as    O
well    O
as    O
in    O
coffee    O
,    O
apple    O
,    O
artichoke    O
,    O
peanut    O
,    O
orange    O
and    O
pineapple    O
.    O

Phenolic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
e.g.    O
chlorogenic    O
acid    O
,    O
caffeic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
p    O
-    O
coumaric    O
acid    O
,    O
ferulic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
p    O
-    O
hydroxybenzoic    O
acid    O
,    O
vanillic    O
acid    O
)    O

Ferulic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Ferulic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
3-methoxy-4-hydroxycinnamic    O
acid    O
)    O
–    O
oats    O
,    O
rice    O
,    O
artichoke    O
,    O
orange    O
,    O
pineapple    O
,    O
apple    O
,    O
peanut    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
3,4-dihydroxy-trans-cinnamate    B-HydroxyAcid114613922
(    O
caffeic    O
acid    O
)    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
3-methoxy-4-hydroxy-trans-cinnamate    B-HydroxyAcid114613922
(    O
ferulic    O
acid    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
N    O
-    O
feruloylglycine    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ferulate    B-HydroxyAcid114613922
and    O
glycine    O
.    O

On    O
exposure    O
to    O
oxygen    O
,    O
ascorbic    O
acid    O
will    O
undergo    O
further    O
oxidative    O
decomposition    O
to    O
various    O
products    O
including    O
diketogulonic    O
acid    O
,    O
xylonic    O
acid    O
,    O
threonic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
and    O
oxalic    O
acid    O
.    O

Kynurenic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

kynurenic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Kynurenic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Dysfunctional    O
states    O
of    O
distinct    O
steps    O
of    O
the    O
kynurenine    O
pathway    O
(    O
e.g.    O
kynurenine    O
,    O
kynurenic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
quinolinic    O
acid    O
,    O
anthranilic    O
acid    O
,    O
3    O
-Hydroxykynurenine    O
)    O
have    O
been    O
described    O
for    O
a    O
number    O
of    O
disorders    O
,    O
e.g.    O
:    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
2,3-dihydroxybenzoate    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
(    O
2,3-dihydroxybenzoyl)adenylate    O
.    O

Salicylates    O
are    O
excreted    O
mainly    O
by    O
the    O
kidneys    O
as    O
salicyluric    O
acid    O
(    O
75%    O
)    O
,    O
free    O
salicylic    O
acid    O
(    O
10%    O
)    O
,    O
salicylic    O
phenol    O
(    O
10%    O
)    O
,    O
and    O
acyl    O
glucuronides    O
(    O
5%    O
)    O
,    O
gentisic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
<    O
1%    O
)    O
,    O
and    O
2,3-dihydroxybenzoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

3-Hydroxyoctanoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

It    O
is    O
also    O
the    O
active    O
component    O
of    O
the    O
prodrug    O
balsalazide    B-HydroxyAcid114613922
along    O
with    O
the    O
inert    O
carrier    O
molecule    O
4-aminobenzoyl    O
-    O
beta    O
-    O
alanine    O
.    O

It    O
is    O
a    O
combination    O
consisting    O
of    O
amoxicillin    O
,    O
a    O
β-lactam    O
antibiotic    O
,    O
and    O
potassium    B-HydroxyAcid114613922
clavulanate    I-HydroxyAcid114613922
,    O
a    O
β-lactamase    O
inhibitor    O
.    O

Augmentin    O
250    O
,    O
for    O
example    O
,    O
contains    O
250    O
mg    O
of    O
amoxicillin    O
and    O
125    O
mg    O
of    O
clavulanic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O

This    O
enzyme    O
participates    O
in    O
clavulanic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
biosynthesis    I-HydroxyAcid114613922
.    O

This    O
enzyme    O
participates    O
in    O
clavulanic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
biosynthesis    I-HydroxyAcid114613922
.    O

Beta    O
-    O
lactamase    O
inhibitors    O
,    O
such    O
as    O
clavulanic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
and    O
sulbactam    O

It    O
is    O
almost    O
invariably    O
sold    O
and    O
used    O
in    O
combination    O
with    O
clavulanate    B-HydroxyAcid114613922
as    O
Timentin    O
.    O

Ticarcillin    O
is    O
also    O
often    O
paired    O
with    O
a    O
β-lactamase    O
inhibitor    O
such    O
as    O
clavulanic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
co    O
-    O
ticarclav    O
)    O
.    O

This    O
product    O
has    O
been    O
synthesized    O
(    O
52%    O
yield    O
)    O
from    O
4-Hydroxyphenylacetic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
via    O
aerobic    O
biotransformation    O
using    O
whole    O
cell    O
cultures    O
of    O
"    O
Arthrobacter    O
protophormiae    O
"    O
.    O

The    O
enzyme    O
4-hydroxyacetophenone    O
monooxygenase    O
,    O
which    O
can    O
be    O
found    O
in    O
"    O
Pseudomonas    O
fluorescens    O
"    O
,    O
uses    O
(    O
4-hydroxyphenyl)ethan-1-one    O
,    O
NADPH    O
,    O
H+    O
and    O
O2    O
to    O
produce    O
4-hydroxyphenyl    B-HydroxyAcid114613922
acetate    I-HydroxyAcid114613922
,    O
NADP+    O
,    O
and    O
H2O.    O

Carnosic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Creams    O
and    O
Ointments    O
:    O
Ointment    O
containing    O
antibiotic    O
like    O
mupirocin    B-HydroxyAcid114613922
2%    O
or    O
a    O
mixture    O
of    O
components    O
like    O
neomycin    O
,    O
nystatin    O
and    O
triamcinolone    O
can    O
be    O
used    O
to    O
control    O
bacterial    O
or    O
mixed    O
bacterial    O
/    O
fungal    O
infections    O
.    O

However    O
,    O
at    O
least    O
in    O
Canadian    O
hospitals    O
,    O
data    O
collected    O
between    O
1999    O
-    O
2005    O
showed    O
rather    O
low    O
rate    O
of    O
resistance    O
of    O
MSSA    O
and    O
MRSA    O
to    O
fusidic    O
acid    O
,    O
and    O
mupirocin    B-HydroxyAcid114613922
was    O
found    O
to    O
be    O
the    O
more    O
problematic    O
topical    O
antibiotic    O
for    O
the    O
aforementioned    O
conditions    O
.    O

However    O
,    O
Pseudomonas    O
aeruginosa    O
produces    O
antimicrobial    O
substances    O
such    O
as    O
pseudomonic    O
acid    O
(    O
that    O
are    O
exploited    O
commercially    O
such    O
as    O
Mupirocin    B-HydroxyAcid114613922
)    O
.    O

Mupirocin    B-HydroxyAcid114613922

Myriocin    B-HydroxyAcid114613922
,    O
also    O
known    O
as    O
antibiotic    O
ISP-1    B-HydroxyAcid114613922
and    O
thermozymocidin    B-HydroxyAcid114613922
,    O
is    O
an    O
atypical    O
amino    O
acid    O
and    O
an    O
antibiotic    O
derived    O
from    O
certain    O
thermophilic    O
fungi    O
.    O

3,11-Dihydroxydodecanoic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922

Japan    O
began    O
screening    O
six    O
-    O
month    O
-    O
olds    O
for    O
neuroblastoma    O
via    O
analysis    O
of    O
the    O
levels    O
of    O
homovanillic    O
acid    O
and    O
vanilmandelic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
in    O
1984    O
.    O

3,4-Dihydroxymandelic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
DOMA    O
)    O
→    O
Vanillylmandelic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
VMA    O
)    O

In    O
organic    O
chemistry    O
,    O
the    O
vanillyl    O
group    O
(    O
also    O
known    O
as    O
vanilloyl    O
)    O
is    O
a    O
functional    O
group    O
.    O
Compounds    O
containing    O
a    O
vanillyl    O
group    O
are    O
called    O
vanilloids    O
,    O
and    O
include    O
vanillin    O
,    O
vanillic    O
acid    O
,    O
capsaicin    O
,    O
vanillylmandelic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
etc    O
.    O

It    O
is    O
becoming    O
common    O
for    O
beta    B-HydroxyAcid114613922
hydroxy    I-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
BHA    O
)    O
peels    O
to    O
be    O
used    O
instead    O
of    O
the    O
stronger    O
alpha    O
hydroxy    O
acid    O
(    O
AHA    O
)    O
peels    O
due    O
to    O
BHA    O
's    O
being    O
oil    O
soluble    O
.    O

A    O
beta    B-HydroxyAcid114613922
hydroxy    I-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
or    O
β-hydroxy    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
BHA    B-HydroxyAcid114613922
)    O
is    O
an    O
organic    O
compound    O
that    O
contains    O
a    O
carboxylic    O
acid    O
functional    O
group    O
and    O
hydroxy    O
functional    O
group    O
separated    O
by    O
"    O
two    O
"    O
carbon    O
atoms    O
.    O

The    O
major    O
metabolites    O
of    O
Oxiracetam    O
include    O
:    O
beta    O
-    O
hydroxy-2-pyrrolidone    O
,    O
N    O
-    O
aminoacetyl    O
-    O
GABOB    B-HydroxyAcid114613922
,    O
GABOB    O
(    O
beta    O
-    O
hydroxy    O
-    O
GABA    O
)    O
and    O
glycine    O
.    O

While    O
many    O
studies    O
cite    O
excitotoxicity    O
,    O
or    O
oxidative    O
stress    O
as    O
likely    O
mechanisms    O
,    O
which    O
may    O
be    O
an    O
effect    O
of    O
the    O
chemical    O
itself    O
,    O
this    O
has    O
led    O
to    O
the    O
search    O
for    O
other    O
mechanisms    O
for    O
the    O
observed    O
toxicity    O
of    O
serotonin    O
neurons    O
and    O
subsequent    O
reduction    O
in    O
5-HT    O
(    O
Serotonin    O
)    O
and    O
5-HIAA    B-HydroxyAcid114613922
(    O
its    O
major    O
metabolite    O
in    O
the    O
body    O
)    O
in    O
vivo    O
following    O
administration    O
.    O

There    O
has    O
also    O
been    O
inconsistency    O
with    O
regards    O
to    O
serum    O
5-HIAA    B-HydroxyAcid114613922
levels    O
,    O
a    O
metabolite    O
of    O
serotonin    O
.    O

Psychopathy    O
was    O
associated    O
in    O
two    O
studies    O
with    O
an    O
increased    O
ratio    O
of    O
HVA    O
(    O
a    O
dopamine    O
metabolite    O
)    O
to    O
5-HIAA    B-HydroxyAcid114613922
(    O
a    O
serotonin    O
metabolite    O
)    O
.    O

The    O
compound    O
itself    O
is    O
not    O
toxic    O
but    O
undergoes    O
lethal    O
synthesis    O
in    O
the    O
body    O
while    O
reacting    O
with    O
coenzyme    O
A    O
,    O
yielding    O
fluoroacetyl    O
-    O
Coenzyme    O
A.    O
This    O
compound    O
reacts    O
with    O
oxaloacetate    O
to    O
form    O
fluorocitrate    B-HydroxyAcid114613922
,    O
which    O
is    O
toxic    O
,    O
being    O
an    O
alternate    O
substrate    O
for    O
aconitase    O
(    O
normal    O
substrate    O
citrate    O
)    O
.    O

Penicitrinol    O
K    O
is    O
a    O
citrinin    B-HydroxyAcid114613922
derivative    O
isolated    O
from    O
marine    O
-    O
derived    O
"    O
Penicillium    O
"    O
.    O

Citrinin    B-HydroxyAcid114613922

Citrinin    B-HydroxyAcid114613922
:    O
Citrinin    O
was    O
first    O
isolated    O
from    O
Penicillium    O
citrinum    O
prior    O
to    O
World    O
War    O
II    O
;    O
subsequently    O
,    O
it    O
was    O
identified    O
in    O
over    O
a    O
dozen    O
species    O
of    O
Penicillium    O
and    O
several    O
species    O
of    O
Aspergillus    O
(    O
e.g.    O
,    O
Aspergillus    O
terreus    O
and    O
Aspergillus    O
niveus    O
)    O
,    O
including    O
certain    O
strains    O
of    O
Penicillium    O
camemberti    O
(    O
used    O
to    O
produce    O
cheese    O
)    O
and    O
Aspergillus    O
oryzae    O
(    O
used    O
to    O
produce    O
sake    O
,    O
miso    O
,    O
and    O
soy    O
sauce    O
)    O
.    O

Citrinin    B-HydroxyAcid114613922
is    O
a    O
mycotoxin    O
which    O
is    O
often    O
found    O
in    O
food    O
.    O

Microbacterium    O
paraoxydans    O
"    O
metabolize    O
(    O
RS)-mandelonitrile    O
to    O
(    O
mandelic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
.    O
"    O
Microbacterium    O
paraoxydans    O
"    O
is    O
a    O
plant    O
growth    O
-    O
promoting    O
bacteria    O
.    O

Mandelate    O
racemase    O
is    O
a    O
bacterial    O
enzyme    O
which    O
catalyzes    O
the    O
interconversion    O
of    O
the    O
enantiomers    O
of    O
mandelate    B-HydroxyAcid114613922
via    O
an    O
enol    O
intermediate    O
.    O

Mandelic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
is    O
an    O
aromatic    O
alpha    B-HydroxyAcid114613922
hydroxy    I-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
with    O
the    O
molecular    O
formula    O
C6H5CH(OH)CO2H.    O
It    O
is    O
a    O
white    O
crystalline    O
solid    O
that    O
is    O
soluble    O
in    O
water    O
and    O
polar    O
organic    O
solvents    O
.    O

It    O
is    O
the    O
drug    O
in    O
the    O
feed    O
additives    O
called    O
Bovatec    B-HydroxyAcid114613922
and    O
Avatec    B-HydroxyAcid114613922
.    O

L-Carnitine    B-HydroxyAcid114613922
is    O
biosynthesized    O
from    O
"    O
N"ε-trimethyllysine    O
.    O

catalyse    O
the    O
stereospecific    O
hydroxylation    O
of    O
γ-butyrobetaine    O
to    O
L-carnitine    B-HydroxyAcid114613922
.    O

Scheme    O
describing    O
the    O
biosynthetic    O
pathway    O
of    O
L-carnitine    B-HydroxyAcid114613922
in    O
humans    O
.    O

Fatty    O
acids    O
are    O
transported    O
into    O
the    O
mitochondria    O
as    O
an    O
acyl-carnitine    B-HydroxyAcid114613922
via    O
the    O
action    O
of    O
the    O
enzyme    O
CAT-1    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
and    O
carnitine    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
O    O
-    O
acetylcarnitine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
octanoyl    O
-    O
CoA    O
and    O
L-carnitine    B-HydroxyAcid114613922
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
L    O
-    O
octanoylcarnitine    O
.    O

Its    O
ingredients    O
are    O
L-carnitine    B-HydroxyAcid114613922
,    O
L    O
-    O
tartaric    O
acid    O
,    O
potassium    O
chloride    O
,    O
L    O
-    O
leucine    O
,    O
isoleucine    O
,    O
valine    O
,    O
nicotinic    O
acid    O
,    O
and    O
biotin    O
.    O

Dupree    O
had    O
an    O
unknown    O
muscular    O
disorder    O
believed    O
to    O
be    O
related    O
to    O
the    O
metabolic    O
cycle    O
and    O
carnitine    B-HydroxyAcid114613922
.    O

Carnitine    B-HydroxyAcid114613922

Various    O
stimulants    O
found    O
in    O
energy    O
drinks    O
include    O
taurine    O
,    O
glucoronolactone    O
,    O
caffeine    O
,    O
B    O
vitamins    O
,    O
guarana    O
,    O
ginseng    O
,    O
ginkgo    O
biloba    O
,    O
L-carnitine    B-HydroxyAcid114613922
,    O
sugars    O
,    O
antioxidants    O
,    O
yerba    O
maté    O
,    O
creatine    O
,    O
and    O
milk    O
thistle    O
.    O

Carnitine    O
-    O
acylcarnitine    O
translocase    O
is    O
responsible    O
for    O
transporting    O
both    O
carnitine    B-HydroxyAcid114613922
-    O
fatty    O
acid    O
complexes    O
and    O
carnitine    B-HydroxyAcid114613922
across    O
the    O
inner    O
mitochondrial    O
membrane    O
.    O

It    O
then    O
exchanges    O
the    O
CoA    O
for    O
carnitine    B-HydroxyAcid114613922
by    O
the    O
action    O
of    O
the    O
enzyme    O
carnitine    O
palmitoyltransferase    O
I.    O

Because    O
there    O
is    O
no    O
transport    O
protein    O
for    O
CoA    O
adducts    O
,    O
acyl    O
groups    O
must    O
enter    O
the    O
mitochondria    O
via    O
a    O
shuttle    O
system    O
involving    O
the    O
small    O
molecule    O
carnitine    B-HydroxyAcid114613922
.    O

Carnitine    B-HydroxyAcid114613922
,    O
a    O
natural    O
substance    O
acquired    O
mostly    O
through    O
the    O
diet    O
,    O
is    O
used    O
by    O
cells    O
to    O
process    O
fats    O
and    O
produce    O
energy    O
.    O

Carnitine    B-HydroxyAcid114613922
is    O
a    O
hydrophilic    O
natural    O
substance    O
acquired    O
mostly    O
through    O
dietary    O
meats    O
and    O
dairy    O
products    O
and    O
is    O
used    O
by    O
cells    O
to    O
transport    O
hydrophobic    O
fatty    O
acids    O
.    O

The    O
standard    O
treatment    O
is    O
chenodeoxycholic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
(    O
CDCA    O
)    O
replacement    O
therapy    O
.    O

The    O
balance    O
between    O
these    O
two    O
steroids    O
determines    O
the    O
relative    O
amounts    O
of    O
the    O
two    O
primary    O
bile    O
acids    O
,    O
cholic    O
acid    O
and    O
chenodeoxycholic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
both    O
of    O
which    O
are    O
secreted    O
in    O
the    O
bile    O
.    O

The    O
natural    O
bile    O
acid    O
,    O
chenodeoxycholic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
was    O
identified    O
in    O
1999    O
as    O
the    O
most    O
active    O
physiological    O
ligand    O
for    O
the    O
farnesoid    O
X    O
receptor    O
(    O
FXR    O
)    O
,    O
which    O
is    O
involved    O
in    O
many    O
physiological    O
and    O
pathological    O
processes    O
.    O

Muricholic    O
acids    O
differ    O
from    O
the    O
more    O
common    O
bile    O
acids    O
,    O
such    O
as    O
cholic    O
acid    O
or    O
chenodeoxycholic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
,    O
by    O
having    O
a    O
hydroxyl    O
group    O
at    O
the    O
6-position    O
.    O

For    O
example    O
,    O
a    O
molecule    O
containing    O
a    O
carboxylic    O
acid    O
moiety    O
and    O
an    O
acid    O
labile    O
moiety    O
might    O
be    O
stable    O
when    O
initially    O
prepared    O
as    O
the    O
salt    O
(    O
e.g.    O
,    O
barium    O
prephenate    B-HydroxyAcid114613922
)    O
but    O
unstable    O
as    O
the    O
free    O
acid    O
(    O
prephenic    B-HydroxyAcid114613922
acid    I-HydroxyAcid114613922
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
L    O
-    O
arogenate    O
and    O
oxaloacetate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
prephenate    B-HydroxyAcid114613922
and    O
L    O
-    O
aspartate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
L    O
-    O
arogenate    O
and    O
2-oxoglutarate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
prephenate    B-HydroxyAcid114613922
and    O
L    O
-    O
glutamate    O
.    O


